pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2023-33-5-679-688pulmo-4352Research ArticleОБЗОРЫREVIEWЗначение N-ацетилцистеина в клинической практикеSignificance of N-acetylcysteine in clinical practicehttps://orcid.org/0000-0002-1620-7159ЛещенкоИ. В.LeshchenkoI. V.

Лещенко Игорь Викторович – д. м. н., профессор кафедры фтизиатрии и пульмонологии Федерального государственного бюджетного образовательного учреждения высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации, главный научный сотрудник научно-клинического отдела Уральского научно-исследовательского института фтизиопульмонологии – филиала Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Министерства здравоохранения Российской Федерации, научный руководитель клиники Общества с ограниченной ответственностью «Медицинское объединение “Новая больница”» главный внештатный специалист-пульмонолог Министерства здравоохранения Свердловской области, заслуженный врач Российской Федерации

620028, Екатеринбург, ул. Репина, 3; 620039, Екатеринбург, 22-го Партсъезда, 50; 620109, Екатеринбург, ул. Заводская, 29

тел.: (343) 246-44-75

Igor V. Leshсhenko, Doctor of Medicine, Professor, Department of Phthisiology and Pulmonology, Federal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Chief Researcher, Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Scientific Director, Limited Liability Company “Novaya bol’nitsa” Clinical Association, Chief Freelance Pulmonologist, Healthcare Ministry of the Sverdlovsk Region, Honored Doctor of the Russian Federation

ul. Repina 3, Ekaterinburg, 620028; ul. 22-go Parts’ezda 50, Ekaterinburg, 620039; ul. Zavodskaya 29, Ekaterinburg, 620109

tel.: (343) 246-44-75

leshchenkoiv@yandex.ruhttps://orcid.org/0000-0001-9565-3570ЭсауловаН. А.EsaulovaN. A.

Эсаулова Наталья Александровна – к. м. н., доцент кафедры фтизиатрии и пульмонологии Федерального государственного бюджетного образовательного учреждения высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; врач-пульмонолог Уральского научно-исследовательского института фтизиопульмонологии – филиала Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Министерства здравоохранения Российской Федерации  

620028, Екатеринбург, ул. Репина, 3; 620039, Екатеринбург, 22-го Партсъезда, 50

тел.: (343) 246-44-75

Natalya A. Esaulovа, Candidate or Medicine, Associate Professor, Department of Phthisiology and Pulmonology, Federal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Pulmonologist, Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia

ul. Repina 3, Ekaterinburg, 620028; ul. 22-go Parts’ezda 50, Ekaterinburg, 620039

tel.: (343) 246-44-75

esanat1@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Уральский научно-исследовательский институт фтизиопульмонологии – филиал Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Министерства здравоохранения Российской Федерации; Общество с ограниченной ответственностью «Медицинское объединение “Новая больница”»РоссияFederal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Limited Liability Company “Novaya bol’nitsa” Clinical AssociationRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Уральский научно-исследовательский институт фтизиопульмонологии – филиал Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of RussiaRussian Federation202305092023335679688Copyright © Лещенко И.В., Эсаулова Н.А., 20232023Лещенко И.В., Эсаулова Н.А.Leshchenko I.V., Esaulova N.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/4352

N-ацетилцистеин (NAC) – муколитическое, антиоксидантное средство – лекарственный препарат с уникальным разнообразием свойств. Клиническое применение NAC охватывает более чем 35-летний период, при этом особое внимание уделяется многогранному действию и широкому спектру показаний для назначения. В литературных источниках содержится информация об эффективности NAC при профилактике нефропатии, индуцированной рентгеноконтрастными веществами, а также о значении NАС в респираторной, коронарной патологии и т. д. Целью обзора явился анализ эффективности и безопасности применения NAC в респираторной клинической практике. Заключение. NAC представляет собой лекарственный препарат с уникальным разнообразием свойств и терапевтических возможностей. В пульмонологической практике доказана эффективность и безопасность препарата в реалиях клинического применения.

N-acetylcysteine (NAC) is a mucolytic and antioxidant with a variety of properties. The clinical use of NAC spans more than 35 years, during which the emphasis has been on a multifaceted action and broad spectrum of therapeutic indications. Information is available on the efficacy of NAC in the prevention of contrast-induced nephropathy, studies on the role of NAC in the treatment of pulmonary and coronary disease, etc. The purpose of this review is to analyze the efficacy and safety of NAC in respiratory clinical practice. Conclusion. NAC is a drug with a unique variety of properties and treatment options. The drug has proven its efficacy and safety in real pulmonology practice.

N-ацетилцистеинмуколитические препаратыантиоксидантыN-acetylcysteinemucolyticsantioxidantsСтатья опубликована при поддержке компании «Замбон». Финансирование исследования осуществлялось компанией «Замбон» без предоставления препарата. Представители компании не принимали участия в подготовке статьи, не несут ответственности за содержание статьи и любые возможные договоренности, относящиеся к данной статье, либо финансовые соглашения с любыми третьими лицами. Мнение представителей компании может отличаться от мнения авторов статьи и редакции.The article was published with support from the Zambon Group. The Zambon Group provided funding for the scientific research, but not the drug products. The representatives of the sponsor did not participate in the writing of this article and are not responsible for the content of the article or any financial or other agreements with third parties in connection with this article. The opinions of the sponsor’s representatives may differ from those of the authors of the article and the editorial board.ReferencesWebb W.R. Clinical evaluation of a new mucolytic agent acetylcysteine. J. Thorac. Cardiovasc. Surg. 1962; 44 (3): 330–343. DOI: 10.1016/S0022-5223(19)32956-3.Webb W.R. Clinical evaluation of a new mucolytic agent acetylcysteine. J. Thorac. Cardiovasc. Surg. 1962; 44 (3): 330–343. DOI: 10.1016/S0022-5223(19)32956-3.Reas H.W. The effect of N-acetylcysteine on the viscosity of tracheobronchial secretion in cystic fibrosis of the pancreas. J. Pediatr. 1963; 62: 31–35. DOI: 10.1016/s0022-3476(63)80067-0.Reas H.W. The effect of N-acetylcysteine on the viscosity of tracheobronchial secretion in cystic fibrosis of the pancreas. J. Pediatr. 1963; 62: 31–35. DOI: 10.1016/s0022-3476(63)80067-0.De Vries N., De Flora S. N-acetyl-l-cysteine. J. Cell Biochem. 1993; 17F: 270–278. DOI: 10.1002/jcb.240531040.De Vries N., De Flora S. N-acetyl-l-cysteine. J. Cell Biochem. 1993; 17F: 270–278. DOI: 10.1002/jcb.240531040.De Flora S., Izzotti A., D'Agostini F., Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am. J. Med. 1991; 91 (3, Suppl. 3): 122–130S. DOI: 10.1016/0002-9343(91)90295-9.De Flora S., Izzotti A., D'Agostini F., Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am. J. Med. 1991; 91 (3, Suppl. 3): 122–130S. DOI: 10.1016/0002-9343(91)90295-9.De Flora S., Cesarone C.F., Balansy R.M. et al. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J. Cell Biochem. Suppl. 1995; 22: 33–41. DOI: 10.1002/jcb.240590806.De Flora S., Cesarone C.F., Balansy R.M. et al. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J. Cell Biochem. Suppl. 1995; 22: 33–41. DOI: 10.1002/jcb.240590806.Fishbane S., Durham J.H., Marzo K., Rudnick M. N-acetylcysteine in the prevention of radiocontrastinduced nephropathy. J. Am. Soc. Nephrol. 2004; 15 (2): 251–260. DOI: 10.1097/01.asn.0000107562.68920.92.Fishbane S., Durham J.H., Marzo K., Rudnick M. N-acetylcysteine in the prevention of radiocontrastinduced nephropathy. J. Am. Soc. Nephrol. 2004; 15 (2): 251–260. DOI: 10.1097/01.asn.0000107562.68920.92.Ignarro L. Endothelium derived nitric oxide: pharmacology and relationship to the actions of organic esters. Pharm. Res. 1989; 6 (8): 651–659. DOI: 10.1023/a:1015926119947.Ignarro L. Endothelium derived nitric oxide: pharmacology and relationship to the actions of organic esters. Pharm. Res. 1989; 6 (8): 651–659. DOI: 10.1023/a:1015926119947.Moklesi B., Leikin J.B., Murray P., Corbridge T.C. Adult toxicology in critical care. Part II: specific poisoning. Chest. 2003; 123 (3): 897–922. DOI: 10.1378/chest.123.3.897.Moklesi B., Leikin J.B., Murray P., Corbridge T.C. Adult toxicology in critical care. Part II: specific poisoning. Chest. 2003; 123 (3): 897–922. DOI: 10.1378/chest.123.3.897.Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of accetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Мed. 1988; 319 (24): 1557–1562. DOI: 10.1056/NEJM198812153192401.Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of accetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Мed. 1988; 319 (24): 1557–1562. DOI: 10.1056/NEJM198812153192401.Tenório M.C.D.S., Graciliano N.G., Moura F.A. et al. N-acetylcysteine (NAC): impacts on human health. Antioxidants. 2021; 10 (6): 967. DOI: 10.3390/antiox10060967.Tenório M.C.D.S., Graciliano N.G., Moura F.A. et al. N-acetylcysteine (NAC): impacts on human health. Antioxidants. 2021; 10 (6): 967. DOI: 10.3390/antiox10060967.Roveta A.M., Debbia E., Schito G., Marchese A. Comparison of the activity of N-acetylcisteine, ambroxol, bromexine and sobrerol on Staphylococcus aureus biofilms. GIMMOC. 2004; 8: 1–12.Roveta A.M., Debbia E., Schito G., Marchese A. Comparison of the activity of N-acetylcisteine, ambroxol, bromexine and sobrerol on Staphylococcus aureus biofilms. GIMMOC. 2004; 8: 1–12.Blasi F., Clive Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI: 10.1016/j.rmed.2016.06.015.Blasi F., Clive Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI: 10.1016/j.rmed.2016.06.015.Van Schooten F.J., Besaratinia A., De Flora S. et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol. Biomarkers Prev. 2002; 11 (2): 167–175. Available at: https://aacrjournals.org/cebp/article/11/2/167/166561/Effects-of-Oral-Administration-of-N-Acetyl-lVan Schooten F.J., Besaratinia A., De Flora S. et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol. Biomarkers Prev. 2002; 11 (2): 167–175. Available at: https://aacrjournals.org/cebp/article/11/2/167/166561/Effects-of-Oral-Administration-of-N-Acetyl-lPapadopoulou E., Hansel J., Lazar Z. et al. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis. Eur. Respir. Rev. 2023; 32 (167): 220141. DOI: 10.1183/16000617.0141-202.Papadopoulou E., Hansel J., Lazar Z. et al. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis. Eur. Respir. Rev. 2023; 32 (167): 220141. DOI: 10.1183/16000617.0141-202.Wei J., Pang C.S., Han J., Yan H. Effect of orally administered N-acetylcysteine on chronic bronchitis: a meta-analysis. Adv. Ther. 2019; 36 (12): 3356–3367. DOI: 10.1007/s12325-019-01111-4.Wei J., Pang C.S., Han J., Yan H. Effect of orally administered N-acetylcysteine on chronic bronchitis: a meta-analysis. Adv. Ther. 2019; 36 (12): 3356–3367. DOI: 10.1007/s12325-019-01111-4.Bisetti A., Mancini C. Mucolytic activity of erdosteine: Double blind clinical trial vs. placebo. Arch. Med. Int. 1995; 47 (4): 89–97. Available at: https://www.researchgate.net/publication/279701340_Mucolytic_activity_of_erdosteine_double_blind_clinical_trial_vs_placeboBisetti A., Mancini C. Mucolytic activity of erdosteine: Double blind clinical trial vs. placebo. Arch. Med. Int. 1995; 47 (4): 89–97. Available at: https://www.researchgate.net/publication/279701340_Mucolytic_activity_of_erdosteine_double_blind_clinical_trial_vs_placeboLi W., Mao B., Wang G. et al. Effect of tanreqing injection on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. Chin. J. Integr. Med. 2010; 16 (2): 131–137. DOI: 10.1007/s11655-010-0131-y.Li W., Mao B., Wang G. et al. Effect of tanreqing injection on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. Chin. J. Integr. Med. 2010; 16 (2): 131–137. DOI: 10.1007/s11655-010-0131-y.Marchioni C.F., Polu J.M., Taytard A. et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33 (11): 612–618. Available at: https://eurekamag.com/research/008/633/008633824.phpMarchioni C.F., Polu J.M., Taytard A. et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33 (11): 612–618. Available at: https://eurekamag.com/research/008/633/008633824.phpZhang Q., Ju Y., Ma Y,. Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018; 97 (45): e13087. DOI: 10.1097/MD.0000000000013087.Zhang Q., Ju Y., Ma Y,. Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018; 97 (45): e13087. DOI: 10.1097/MD.0000000000013087.Buha I., Mirić M., Agić A. et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease. Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (13): 4809–4815. DOI: 10.26355/eurrev_202207_29206.Buha I., Mirić M., Agić A. et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease. Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (13): 4809–4815. DOI: 10.26355/eurrev_202207_29206.Papi A., Zheng J., Criner G.J. et al. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study. Respir. Med. 2019; 147: 37–43. DOI: 10.1016/j.rmed.2018.12.014.Papi A., Zheng J., Criner G.J. et al. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study. Respir. Med. 2019; 147: 37–43. DOI: 10.1016/j.rmed.2018.12.014.Riise G.C., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur. Respir. J. 1994; 7 (1): 94–101. DOI: 10.1183/09031936.94.07010094.Riise G.C., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur. Respir. J. 1994; 7 (1): 94–101. DOI: 10.1183/09031936.94.07010094.Holdiness M.R. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokinet. 1991; 20 (2): 123–134. DOI: 10.2165/00003088-199120020-00004.Holdiness M.R. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokinet. 1991; 20 (2): 123–134. DOI: 10.2165/00003088-199120020-00004.Decramer M., Rutten-van Mölken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005; 365 (9470): 1552–1560. DOI: 10.1016/S0140-6736(05)66456-2.Decramer M., Rutten-van Mölken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005; 365 (9470): 1552–1560. DOI: 10.1016/S0140-6736(05)66456-2.Министерство здравоохранения Российской Федерации. Хроническая обструктивная болезнь легких: Клинические рекомендации. 2021. Доступно на: https://spulmo.ru/upload/kr/HOBL_2021.pdf?ysclid=lmajgdp9yl326639003Ministry of Health of the Russian Federation. [Chronic obstructive pulmonary disease: Clinical guidelines]. 2021. Available at: https://spulmo.ru/upload/kr/HOBL_2021.pdf?ysclid=lmajgdp9yl326639003 (in Russian).Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.Министерство здравоохранения Российской Федерации. Временные методические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (14.12.22). Доступно на: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf?1671088207Ministry of Health of the Russian Federation. [The Temporary Guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)]. Version 17 (December 14, 2022). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf?1671088207 (in Russian).Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017; 39 (5): 517–528. DOI: 10.1007/s00281-017-0639-8.Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017; 39 (5): 517–528. DOI: 10.1007/s00281-017-0639-8.Ibrahim H., Perl A., Smith D. et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin. Immunol. 2020; 219: 108544. DOI: 10.1016/j.clim.2020.108544.Ibrahim H., Perl A., Smith D. et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin. Immunol. 2020; 219: 108544. DOI: 10.1016/j.clim.2020.108544.Гайнитдинова В.В., Авдеев С.Н., Мержоева З.М. и др. Опыт применения N-ацетилцистеина в комплексном лечении среднетяжелой COVID-ассоциированной пневмонии. Пульмонология. 2021; 31 (1): 21–29. DOI: 10.18093/0869-0189-2021-31-1-21-29.Gainitdinova V.V., Avdeev S.N., Merzhoeva Z.M. et al. [N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia]. Pul'monologiya. 2021; 31 (1): 21–29. DOI: 10.18093/0869-0189-2021-31-1-21-29 (in Russian).Zafarullah M., Li W.Q., Sylvester J., Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003; 60 (1): 6–20. DOI: 10.1007/s000180300001.Zafarullah M., Li W.Q., Sylvester J., Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003; 60 (1): 6–20. DOI: 10.1007/s000180300001.Sadowska A.M., Manuel-Y-Keenoy B., De Backer W.A. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm. Pharmacol. Ther. 2007; 20 (1): 9–22. DOI: 10.1016/j.pupt.2005.12.007.Sadowska A.M., Manuel-Y-Keenoy B., De Backer W.A. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm. Pharmacol. Ther. 2007; 20 (1): 9–22. DOI: 10.1016/j.pupt.2005.12.007.Wolcott, R.D., Ehrlich, G.D. Biofilms and chronic infections. JAMA. 2008; 299 (22): 2682–2684. DOI: 10.1001/jama.299.22.2682.Wolcott, R.D., Ehrlich, G.D. Biofilms and chronic infections. JAMA. 2008; 299 (22): 2682–2684. DOI: 10.1001/jama.299.22.2682.Pérez-Giraldo C., Rodríguez-Benito A., Morán F.J. et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J. Antimicrob Chemother. 1997; 39 (5): 643–646. DOI: 10.1093/jac/39.5.643.Pérez-Giraldo C., Rodríguez-Benito A., Morán F.J. et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J. Antimicrob Chemother. 1997; 39 (5): 643–646. DOI: 10.1093/jac/39.5.643.Министерство здравоохранения Российской Федерации. Острый бронхит у взрослых: Клинические рекомендации. 2022. Доступно на: https://spulmo.ru/upload/kr/OB_2022.pdf?ysclid=lmak85iv12292497995Ministry of Health of the Russian Federation. [Acute bronchitis in adults: Clinical guidelines]. 2022. Available at: https://spulmo.ru/upload/kr/OB_2022.pdf?ysclid=lmak85iv12292497995 (in Russian).Izquierdo J.L., Soriano J.B., González Y. et al. Use of N-acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Sci. Prog. 2022; 105 (1): 368504221074574. DOI: 10.1177/00368504221074574.Izquierdo J.L., Soriano J.B., González Y. et al. Use of N-acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Sci. Prog. 2022; 105 (1): 368504221074574. DOI: 10.1177/00368504221074574.

The authors declare that there are no conflicts of interest present.